OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Short Interest Update

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) was the recipient of a large decline in short interest during the month of August. As of August 14th, there was short interest totaling 83,450 shares, a decline of 38.4% from the July 30th total of 135,370 shares. Currently, 0.3% of the company’s shares are sold short. Based on an average trading volume of 69,382 shares, the days-to-cover ratio is currently 1.2 days.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of OKYO Pharma in a research note on Friday, July 17th. HC Wainwright decreased their target price on shares of OKYO Pharma from $7.00 to $5.00 and set a “buy” rating for the company in a research note on Monday, July 13th. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, OKYO Pharma currently has a consensus rating of “Hold” and a consensus price target of $5.67.

OKYO Pharma Price Performance

Shares of OKYO stock traded up $0.05 during mid-day trading on Wednesday, hitting $1.56. The company had a trading volume of 3,805 shares, compared to its average volume of 153,061. The stock’s 50 day moving average price is $1.55 and its 200-day moving average price is $1.61. OKYO Pharma has a 52-week low of $1.34 and a 52-week high of $3.20.

Institutional Investors Weigh In On OKYO Pharma

Large investors have recently added to or reduced their stakes in the stock. Citadel Advisors LLC purchased a new position in shares of OKYO Pharma in the 3rd quarter valued at $31,000. XTX Topco Ltd purchased a new position in shares of OKYO Pharma in the fourth quarter worth about $36,000. Finally, Renaissance Technologies LLC lifted its stake in OKYO Pharma by 235.0% during the 4th quarter. Renaissance Technologies LLC now owns 138,000 shares of the company’s stock valued at $286,000 after acquiring an additional 96,800 shares during the period. 2.97% of the stock is owned by hedge funds and other institutional investors.

OKYO Pharma Company Profile

Okyo Pharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for inflammatory and fibrotic diseases. The company’s pipeline is built on proprietary Fc-fusion technology designed to modulate immune responses associated with conditions such as diabetic nephropathy and chronic graft-versus-host disease. Okyo Pharma seeks to address significant unmet medical needs by targeting key cytokine pathways involved in tissue inflammation and fibrosis.

Okyo Pharma’s lead product candidate, OK-101, is an Fc-fusion protein in Phase 2 development for the treatment of diabetic kidney disease.